CD19‐directed chimeric antigen receptor T‐cell therapy (CAR‐T) is another novel immunotherapy approach that has recently demonstrated high response rates among R/R BV‐MCL patients in the pivotal ZUMA‐2 trial (92.9%; n = 13/14) [19]. Here, CD19 is linked to mantle cell lymphoma.